Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA
Pharmaceutical Investing Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
Pharmaceutical Investing Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
